Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 (NUCKS1) mRNA 3' untranslated region (3' UTR) is a critical regulatory element that governs the expression of the NUCKS1 protein, a key player in DNA repair and cell cycle regulation (UniProt: Q9H1E3). This 3' UTR contains multiple binding sites for microRNAs, such as miR-137, which normally suppress NUCKS1 expression; however, the loss of this regulation is frequently associated with the progression of various cancers, including breast and colorectal cancer (PubMed: 30217975, PubMed: 25333241). Beyond oncology, the NUCKS1 transcript is implicated in metabolic pathways, where its levels influence insulin signaling and obesity (PubMed: 25605870). From a therapeutic perspective, the NUCKS1 mRNA 3' UTR is a target for RNA-based interventions, such as antisense oligonucleotides (ASOs) or microRNA mimics, designed to downregulate the protein in disease states. While no small-molecule drugs currently target this region, it represents a significant opportunity for precision oncology and metabolic disease management. Challenges for this target include ensuring tissue-specific delivery and minimizing off-target hybridization. Overall, the NUCKS1 mRNA 3' UTR is a vital node in the post-transcriptional landscape of cancer and metabolic disease.
Modulation of protein expression through antisense-mediated mRNA degradation or steric hindrance of microRNA binding sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 mRNA 3' untranslated region (NUCKS1 mRNA 3' UTR).